The global ECMO Machine Market was valued at USD 0.62 billion in 2024 and reached USD 0.65 billion in 2025. It is projected to grow at a CAGR of 5.8% from 2025 to 2030, achieving an estimated value of USD 0.86 billion by 2030.
This market growth is primarily driven by the rising prevalence of cardiopulmonary conditions such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and advanced heart failure. With pollution, lifestyle-related disorders, and aging populations on the rise, hospitals are increasingly relying on extracorporeal membrane oxygenation (ECMO) machines for advanced life support when conventional therapies fail.
Key Market Drivers: Rising Cardiac and Respiratory Disorders
ECMO systems have become essential in tertiary care hospitals, especially for patients unresponsive to traditional ventilation or medication-based therapies.
Clinical studies show that ECMO significantly improves survival rates in patients with severe ARDS or cardiac failure when used as a last-resort intervention.
Hospitals across North America and Europe are rapidly expanding ECMO-equipped intensive care units (ICUs) to handle growing case volumes. The demand is further amplified by an increase in heart failure patients awaiting transplants, where ECMO acts as a bridge-to-transplant support system.
As global cases of cardiac and respiratory morbidity continue to rise, ECMO adoption is expected to accelerate—helping hospitals reduce mortality rates in critical care scenarios.
Download PDF Brochure
Explore detailed insights, trends, and forecasts in the ECMO market report.
ECMO Machine Market Segmentation
By Product Type
-
ECMO Machines
-
Components (Largest Segment, 2024)
In 2024, the components segment dominated the market, driven by continuous innovation in oxygenators, centrifugal pumps, and smart digital controllers.
Technological breakthroughs include:
-
Polymethyl pentene (PMP) hollow-fiber oxygenators for enhanced gas exchange and longer usage.
-
Centrifugal pumps that minimize blood trauma compared to traditional roller pumps.
-
Biocompatible cannula coatings that improve flow dynamics and patient safety.
-
Smart controllers with real-time monitoring for blood flow, temperature, and oxygenation.
Because full ECMO machines are not frequently replaced, hospitals increasingly upgrade components to improve clinical outcomes—making this segment the backbone of market growth.
By Patient Type
The ECMO market is segmented into adults, pediatrics, and neonates, with adults dominating in 2024.
Adults face higher risks due to lifestyle-related diseases such as obesity, diabetes, hypertension, and smoking-related lung disorders—conditions that often lead to acute respiratory failure or cardiac arrest, where ECMO becomes lifesaving.
Rising rates of metabolic syndrome and sedentary lifestyles in both developed and emerging economies continue to expand the adult ECMO patient pool.
Regional Insights: North America Leads ECMO Adoption
North America remains the largest regional market for ECMO systems, with the United States leading in early adoption and technological innovation.
Key factors driving regional dominance include:
-
Rapid integration of portable ECMO systems and hybrid circuits in hospitals.
-
Strong R&D investments from medical device companies and healthcare institutions.
-
Frequent clinical trials and pilot programs for next-generation ECMO designs.
The region’s advanced healthcare infrastructure, coupled with a culture of early technology adoption, gives North America a competitive edge over Europe and Asia-Pacific.
Request Sample Pages
Get access to data tables, charts, and detailed competitive analysis.
Leading Companies in the ECMO Machine Market
Major players driving innovation and expansion in the global ECMO machine market include:
-
Fresenius Medical Care AG & Co. KGaA (Germany)
-
Getinge AB (Sweden)
-
Medtronic (Ireland)
-
Terumo Corporation (Japan)
-
Nipro Corporation (Japan)
-
LivaNova PLC (UK)
-
Weigao Group Co., Ltd. (China)
-
Abbott Laboratories (US)
-
MicroPort Scientific Corporation (China)
-
Eurosets S.r.l. (Italy)
-
Spectrum Medical Ltd. (UK)
-
Senko Medical Instrument Mfg. Co., Ltd. (Japan)
-
Chalice Medical Ltd. (UK)
-
magAssist Co., Ltd. (China)
-
Braile Biomédica (Brazil)
-
GizmoMed Private Limited (India)
These companies are actively engaging in product launches, acquisitions, and strategic partnerships to strengthen their global presence.
Company Spotlight
Getinge AB (Sweden)
Getinge AB stands as a global leader in ECMO technology, offering advanced life support systems with intuitive user interfaces and enhanced monitoring capabilities.
The company focuses on oxygenator efficiency, reducing hemolysis, and expanding training programs for clinical staff—ensuring both safety and reliability in critical care environments.
Getinge’s strong global distribution and deep hospital partnerships position it at the forefront of extracorporeal life support innovation.
Medtronic (Ireland)
Medtronic leverages its expertise in cardiopulmonary and perfusion technologies to strengthen its ECMO offerings.
Its focus on biocompatible coatings, advanced monitoring, and infection prevention enhances patient outcomes and system reliability.
With a robust global network and investment in clinician education, Medtronic continues to set standards in life-saving ECMO solutions worldwide.
Future Outlook: A Vital Lifeline for Critical Care
As the incidence of respiratory failure and cardiac emergencies continues to rise globally, ECMO systems are evolving into essential tools in modern critical care.
Technological advancements—combined with greater clinician training and affordability improvements—will continue to drive ECMO adoption across hospitals worldwide.
The ECMO machine market outlook (2025–2030) remains strong, reflecting the healthcare industry’s growing emphasis on advanced life support systems that save lives when conventional therapies fall short.